REIG JOFRE submits press release on the results of the third quarter of 2023

REIG JOFRE increased 22% in revenue and 24% in EBITDA up to the 3rd quarter of 2023.

REIG JOFRE reaches 237 million euros of sales, 22% above the first nine months of 2022, due to the notable progression in the Specialty Pharmacare Division and the greater utilisation of the capacity of the new Barcelona plant. Profitability was also improved, with EBITDA growth of 24% to reach 26.2 million euros compared to 21.2 million euros up to September of the previous year.

The Specialty Pharmacare division, focused on the prescription medical product, could close with the highest growth in revenue by 34%. The division with the greatest weight in sales, Pharmaceutical Technologies, dedicated to injectable products and antibiotics, achieved a growth of 19%, whereas the Consumer Healthcare division, the consumer products division, under the FORTE PHARMA brand, in the French, Belgian and Spanish markets, as well as Reig Jofre’s OTC products, grew by 11%.

REIG JOFRE consolidates a growth in sales and profitability of over 20% and expects to end the year with over 300 million euros in revenue. In June, it signed a four-year agreement with the EU capacity reserve for vaccine manufacturing in the event of a health emergency.

Descargue el documento completo (PDF)